Emerging as the pharmaceutical landscape, retatrutide represents a significant advance in obesity treatment space. This unique dual activator targeting both GLP-1 and GIP receptors has shown remarkable performance in research trials , suggesting a improved ability to promote body loss and address associated metabolic complications . While currently